Using a stem cell-derived therapeutic developed over more than a decade in Dr. David Gamm’s lab at UW-Madison, BlueRock Therapeutics has treated the first patient in a new Phase 1/2a clinical trial aimed at a group of …
Clinical Trial
McPherson ERI research featured on Chancellor’s new Research Moves Us Forward webpage
We’re pleased that Chancellor Mnookin has chosen to highlight research from MERI Director David Gamm’s lab to launch her new webpage on transformative, federally funded work happening right now at UW-Madison. You can read about …
Gamm Lab Discoveries Culminate in FDA Approval of a Clinical Trial for the Treatment of Inherited Photoreceptor Diseases
BlueRock Therapeutics LP, a clinical stage cell therapy company and subsidiary of Bayer AG, today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for OpCT-001, …